FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Nolet Chris
2. Issuer Name and Ticker or Trading Symbol

POLARITYTE, INC. [ PTE ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD
3. Date of Earliest Transaction (MM/DD/YYYY)

1/12/2023
(Street)

NEWARK, CA 94560
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/12/2023  M  36497 (1)D$0 14403 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy) $22.50 1/12/2023  M     3078 (2)  (2)4/6/2030 Common Stock 9235 $0.00 6157 D  

Explanation of Responses:
(1) Pursuant to the issuer's non-executive director compensation plan the reporting person was issued 50,900 Restricted Stock Units vesting in equal installments quarterly in arrears, which were previously reported on Form 4 under Table I. As of the date of the reporting person's end of service as a director on January 12, 2023, 36,497 restricted stock units that had not vested as of that date were forfeited.
(2) The stock option was granted 04/06/2020, and reported under Table II of Form 4. The number of derivative securities and price have been adjusted to give effect to a 25-to-1 reverse stock split in May 2022. As of the date of the reporting person's end of service as a director on January 12, 2023, 3,078 stock options that had not vested as of that date were forfeited. The remaining 6,157 stock options were fully vested as of 04/06/2022, and are presently exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Nolet Chris
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK, CA 94560
X



Signatures
/s/ Chris Nolet1/17/2023
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
PolarityTE (NASDAQ:PTE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more PolarityTE Charts.
PolarityTE (NASDAQ:PTE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more PolarityTE Charts.